CAS 1374248-81-3

Atogepant

CAS : 1374248-81-3

Formule : C₂₉H₂₃F₆N₅O₃

Masse moléculaire : 603.53

Ref: 4Z-A-389001

Atogepant-d4

CAS : 1374248-81-3

Formule : C₂₉H₁₉D₄F₆N₅O₃

Masse moléculaire : 607.55

Ref: 4Z-A-389011

Atogepant

CAS : 1374248-81-3

Atogepant

Degré de pureté : ≥98%

Masse moléculaire : 603.52g/mol

Ref: 54-BUP03384

Atogepant-d4 (Spiro Ring-d4)

CAS : 1374248-81-3

Formule : C₂₉H₁₉D₄F₆N₅O₃

Masse moléculaire : 607.55

Ref: 4Z-A-389002

Atogepant

CAS : 1374248-81-3

Atogepant (MK-8031) is an orally available, selective and potent calcitonin gene-related peptide receptor (CGRP) antagonist for the study of migraine.

Formule : C₂₉H₂₃F₆N₅O₃

Degré de pureté : 99.66%

Couleur et forme : Solid

Masse moléculaire : 603.52

Ref: TM-T26682

Atogepant

CAS : 1374248-81-3

Atogepant is a drug for the treatment of migraine that belongs to the group of anti-migraine drugs. It has been shown to inhibit the synthesis of cholesterol, which may be one of its mechanisms for prevention of migraines. Atogepant also inhibits microbial infections through inhibition of growth and can be used as a prophylactic agent against bacterial and viral infections. Atogepant is not active against fungi or parasites. The drug has been observed to have few side effects in women, and it does not affect liver function. It is thought that atogepant binds to a receptor on trigeminal nerve cells, which leads to activation of these cells and subsequent relief from migraine pain.

Formule : C₂₉H₂₃F₆N₅O₃

Degré de pureté : Min. 95%

Masse moléculaire : 603.52 g/mol

Ref: 3D-FA165700